Artificial intelligence to improve drug combination design and personalized medicine

September 25, 2018, SLAS (Society for Laboratory Automation and Screening)
Harnessing Artificial Intelligence toImprove Drug Combination Design and Personalized Medicine. Credit: Zac Goh

A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine. The auto-commentary builds on a study recently published by the authors in Science Translational Medicine about an artificial intelligence (AI) platform, Quadratic Phenotypic Optimization Platform (QPOP), that substantially improves combination therapy in bortezomib-resistant multiple myeloma to identify the best drug combinations for individual multiple myeloma patients.

It is now evident that complex diseases, such as cancer, often require effective combinations to make any significant therapeutic impact. As the drugs in these combination therapies become increasingly specific to molecular targets, designing effective drug combinations as well as choosing the right drug combination for the right patient becomes more difficult.

Artificial intelligence is having a positive impact on and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, QPOP and other small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling. Furthermore, because of the efficiency of the platform, QPOP can also be applied towards precious patient samples to help optimize and personalize combination therapy.

Explore further: Researchers develop AI platform to rapidly identify optimal personalised drug combinations for myeloma patients

More information: Masturah Bte Mohd Abdul Rashid et al, Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine, SLAS TECHNOLOGY: Translating Life Sciences Innovation (2018). DOI: 10.1177/2472630318800774

Masturah Bte Mohd Abdul Rashid et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP), Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aan0941

Related Stories

Researchers use AI to treat metastatic cancer patient

September 4, 2018

A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to treat a patient with advanced cancer, completely halting disease ...

Miniature testing of drug pairs on tumour biopsies

June 22, 2018

Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in ...

Recommended for you

Permanent, wireless self-charging system using NIR band

October 8, 2018

As wearable devices are emerging, there are numerous studies on wireless charging systems. Here, a KAIST research team has developed a permanent, wireless self-charging platform for low-power wearable electronics by converting ...

Facebook launches AI video-calling device 'Portal'

October 8, 2018

Facebook on Monday launched a range of AI-powered video-calling devices, a strategic revolution for the social network giant which is aiming for a slice of the smart speaker market that is currently dominated by Amazon and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.